Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 613

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure: The PRECISE Trial

Packer, Milton, Colucci, Wilson S., Sackner-Bernstein, Jonathan D., Liang, Chang-seng, Goldscher, David A., Freeman, Israel, Kukin, Marrick L., Kinhal, Vithal, Udelson, James E., Klapholz, Marc, Gottlieb, Stephen S., Pearle, David, Cody, Robert J., Gregory, John J., Kantrowitz, Nikki E., LeJemtel, Thierry H., Young, Sarah T., Lukas, Mary Ann, Shusterman, Neil H.·1996·Circulation

Abstract

Background Carvedilol has improved the symptomatic status of patients with moderate to severe heart failure in single-center studies, but its clinical effects have not been evaluated in large, multicenter trials. Methods and Results We enrolled 278 patients with moderate to severe heart failure (6-minute walk distance, 150 to 450 m) and a left ventricular ejection fraction ≤0.35 at 31 centers. After an open-label, run-in period, each patient was randomly assigned (double-blind) to either placebo (n=145) or carvedilol (n=133; target dose, 25 to 50 mg BID) for 6 months, while background therapy with digoxin, diuretics, and an ACE inhibitor remained constant. Compared with placebo, patients in the carvedilol group had a greater frequency of symptomatic improvement and lower risk of clinical deterioration, as evaluated by changes in the NYHA functional class (P=.014) or by a global assessment of progress judged either by the patient (P=.002) or by the physician (P<.001). In addition, treatment with carvedilol was associated with a significant increase in ejection fraction (P<.001) and a significant decrease in the combined risk of morbidity and mortality (P=.029). In contrast, carvedilol therapy had little effect on indirect measures of patient benefit, including changes in exercise tolerance or quality-of-life scores. The effects of the drug were similar in patients with ischemic heart disease or idiopathic dilated cardiomyopathy as the cause of heart failure. Conclusions These findings indicate that, in addition to its favorable effects on survival, carvedilol produces important clinical benefits in patients with moderate to severe heart failure treated with digoxin, diuretics, and an ACE inhibitor. (Circulation. 1996;94:2793-2799.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.94.11.2793

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 613

Metadata

Authors
Packer, M., Colucci, W. S., Sackner-Bernstein, J. D., Liang, C.-S., Goldscher, D. A., Freeman, I., Kukin, M. L., Kinhal, V., Udelson, J. E., Klapholz, M., Gottlieb, S. S., Pearle, D., Cody, R. J., Gregory, J. J., Kantrowitz, N. E., LeJemtel, T. H., Young, S. T., Lukas, M. A., & Shusterman, N. H.
Venue
Circulation
Published
1996-12
Volume
94
Issue
11
Pages
2793-2799
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2088138316
Cited by
613
References
40
FWCI
34.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure: The PRECISE Trial. https://app.cochat.ai/papers/10.1161/01.cir.94.11.2793
The paper
Packer, M., Colucci, W. S., Sackner-Bernstein, J. D., Liang, C.-S., Goldscher, D. A., Freeman, I., Kukin, M. L., Kinhal, V., Udelson, J. E., Klapholz, M., Gottlieb, S. S., Pearle, D., Cody, R. J., Gregory, J. J., Kantrowitz, N. E., LeJemtel, T. H., Young, S. T., Lukas, M. A., & Shusterman, N. H. (1996). Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure: The PRECISE Trial. Circulation. https://doi.org/10.1161/01.cir.94.11.2793

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.